Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 3
1992 1
1993 1
1994 2
1995 3
1996 8
1997 12
1998 13
1999 6
2000 10
2001 6
2002 14
2003 19
2004 14
2005 30
2006 27
2007 18
2008 15
2009 8
2010 3
2011 8
2012 6
2013 9
2014 5
2015 7
2016 4
2017 4
2018 3
2019 4
2020 3
2021 1
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 16565256

259 results
Results by year
Filters applied: . Clear all
Page 1
Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study.
Remuzzi G, Macia M, Ruggenenti P. Remuzzi G, et al. J Am Soc Nephrol. 2006 Apr;17(4 Suppl 2):S90-7. doi: 10.1681/ASN.2005121324. J Am Soc Nephrol. 2006. PMID: 16565256 Free article. Review.
Primary prevention of renal failure in diabetic patients: the Bergamo Nephrologic Diabetes Complication Trial.
Ruggenenti P, Remuzzi G. Ruggenenti P, et al. J Hypertens Suppl. 1998 Jan;16(1):S95-7. J Hypertens Suppl. 1998. PMID: 9534106 Clinical Trial.
Preventing microalbuminuria in type 2 diabetes.
Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Ruggenenti P, et al. N Engl J Med. 2004 Nov 4;351(19):1941-51. doi: 10.1056/NEJMoa042167. Epub 2004 Oct 31. N Engl J Med. 2004. PMID: 15516697 Free article. Clinical Trial.
Preventing microalbuminuria in patients with type 2 diabetes.
Jermendy G, Ruggenenti P. Jermendy G, et al. Diabetes Metab Res Rev. 2007 Feb;23(2):100-10. doi: 10.1002/dmrr.693. Diabetes Metab Res Rev. 2007. PMID: 17094161 Review.
Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial.
Ruggenenti P, Perna A, Ganeva M, Ene-Iordache B, Remuzzi G; BENEDICT Study Group. Ruggenenti P, et al. J Am Soc Nephrol. 2006 Dec;17(12):3472-81. doi: 10.1681/ASN.2006060560. Epub 2006 Nov 2. J Am Soc Nephrol. 2006. PMID: 17082240 Free article. Clinical Trial.
The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics.
BENEDICT Group. BENEDICT Group. Control Clin Trials. 2003 Aug;24(4):442-61. doi: 10.1016/s0197-2456(03)00028-x. Control Clin Trials. 2003. PMID: 12865039 Clinical Trial.
Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients.
Cooper ME. Cooper ME. J Hypertens Suppl. 1996 Dec;14(6):S11-4. J Hypertens Suppl. 1996. PMID: 9023709 Review.
Losartan in diabetic nephropathy.
Perico N, Ruggenenti P, Remuzzi G. Perico N, et al. Expert Rev Cardiovasc Ther. 2004 Jul;2(4):473-83. doi: 10.1586/14779072.2.4.473. Expert Rev Cardiovasc Ther. 2004. PMID: 15225108 Review.
Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR. Weir MR. Clin Ther. 2007 Sep;29(9):1803-24. doi: 10.1016/j.clinthera.2007.09.019. Clin Ther. 2007. PMID: 18035185 Review.
Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control.
Hunsicker LG. Hunsicker LG. J Manag Care Pharm. 2004 Sep;10(5 Suppl A):S12-7. doi: 10.18553/jmcp.2004.10.S5-A.S12. J Manag Care Pharm. 2004. PMID: 15369420 Review.
259 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback